Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2016. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding specific share transactions rather than a financial performance report.
Material Changes
The filing discloses an increase in the notional allocation of GSK American Depositary Shares (ADSs) on April 8, 2016. This change resulted from the revaluation of the cash element of a notional investment held within the GSK 401(K) plan. The transaction price was $41.55 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is strictly a notification of a specific transaction.
Important Facts for Investors
- Transaction Date: April 8, 2016 (notified April 11, 2016).
- Connected Person: Dr K Slaoui (Connected Person of Dr M M Slaoui).
- Transaction Type: Increase in notional allocation of ADSs.
- Quantity: 9 ADSs.
- Price: $41.55 per ADS.
- Context: Revaluation of cash element within the GSK 401(K) plan.